Linus Pauling won two Nobel Prizes and then spent the end of his career insisting that very high doses of vitamin C could help people with cancer. Two large Mayo Clinic trials tested the idea, found no benefit, and the matter was widely considered closed.
There is a detail in that history that neither the trials' defenders nor their critics emphasized at the time. Pauling and his collaborator, the Scottish physician Ewan Cameron, started their patients on intravenous vitamin C and only later switched to tablets. The Mayo trials used tablets only.
That difference is not a technicality. It may be the whole story.
The Gut Sets a Ceiling That Tablets Cannot Clear
Vitamin C absorption from the digestive tract saturates. Past a modest daily dose, the body simply stops taking in appreciably more, and blood levels plateau no matter how many tablets someone swallows.
An intravenous infusion bypasses that limit entirely. The Linus Pauling Institute at Oregon State University notes that, compared with oral dosing, intravenous administration can produce plasma vitamin C concentrations 30 to 70 times higher, and University of Iowa researchers have reported still larger gaps at pharmacologic doses.
Writing in The Conversation, Justin Stebbing, professor of biomedical sciences at Anglia Ruskin University, lays out the consequence: at those extreme concentrations, vitamin C starts behaving differently inside the body.
That reframes the Mayo results. They remain valid evidence that swallowing high-dose vitamin C does not help people with established cancer live longer. They were never a test of the thing Pauling originally did.
A Molecule That Switches Sides
At everyday concentrations, vitamin C is an antioxidant. It donates electrons to neutralize reactive molecules and protect cells. That is the version on the supplement label.
At concentrations achievable only by infusion, and particularly in the tumor microenvironment, it can flip roles and act as a pro-oxidant, helping generate hydrogen peroxide.
Cancer cells appear disproportionately vulnerable to that pulse. They grow rapidly, often in areas with poor blood supply, generate large quantities of their own reactive molecules, and run their internal cleanup systems near capacity. Add a sudden load of hydrogen peroxide and many tip over, with damage to DNA, lipids, proteins, and the machinery that produces energy. Normal cells, under less strain and better defended, are more likely to survive.
Laboratory work has added detail. National Institutes of Health researchers reported in the Proceedings of the National Academy of Sciences that pharmacologic ascorbate acts as a pro-oxidant, generating hydrogen peroxide in the fluid surrounding tumors but not in blood. Iowa researchers subsequently reported that tumor cells carrying elevated pools of redox-active iron and higher baseline oxidative stress appear particularly susceptible to that chemistry.
At those levels, as Stebbing puts it, vitamin C behaves less like a supplement and more like a weak, selective chemotherapy drug. Crucially, the required doses cannot be achieved with pills.
What the Human Evidence Actually Shows
This is where enthusiasm has to stop, and the honest summary is less satisfying than either side of the old argument.
Small trials have delivered high-dose intravenous vitamin C to patients with hard-to-treat cancers, including ovarian, pancreatic, and brain tumors. Many patients tolerate large doses several times a week without serious side effects. That is a safety observation, not an efficacy one.
The most cited efficacy signal comes from pancreatic cancer, where Iowa investigators added high-dose ascorbate to standard chemotherapy and reported roughly doubled median overall survival, with the data safety monitoring board stopping enrollment early. That is a single trial in a small population, and it has not yet been replicated in a large confirmatory study. Other trials show no clear benefit. The evidence base is small, varied and not yet conclusive.
The one reasonably consistent signal is quality of life. Patients receiving vitamin C alongside chemotherapy often report less fatigue, less pain, and fewer side effects such as nausea. For someone with advanced disease, that is nothing, even though it is not the cure Pauling promised.
Laboratory work also points to subtler roles. Vitamin C participates in enzymes that influence how DNA is chemically marked and read, and in how cells respond to low oxygen. Some experiments show that high concentrations make cancer cells less aggressive or more sensitive to treatment. Early suggestions that vitamin C helps the immune system recognize tumors remain speculative.
A summary of the argument circulated widely this month. What does not exist is a large, definitive randomized trial showing that intravenous vitamin C prolongs life for most cancer patients.
Why This Is Not an Argument for Supplements
The most likely way this story gets misread is as permission to take more vitamin C, and the science points in precisely the opposite direction.
The entire mechanism depends on concentrations that oral dosing cannot produce. Taking more tablets does not move a person any closer to the effect. It moves them nowhere, because absorption has already stopped.
Infusions are also not harmless. Problems can occur, particularly in people with impaired kidney function or certain rare inherited enzyme deficiencies, which is why this is not a wellness drip that belongs in a storefront clinic.
The appropriate setting is a clinical trial or carefully supervised medical care. Anyone with cancer considering high-dose vitamin C should raise it with their oncologist rather than a supplement retailer, and no one should substitute it for standard treatment. Patients interested in participating can ask their oncology team about registered trials.
Key Questions Answered
What did the Mayo Clinic trials actually test? They tested high-dose oral vitamin C in patients with advanced cancer and found no survival benefit. Pauling and Cameron had started their patients on intravenous vitamin C before switching to tablets, so the Mayo trials did not test the delivery route Pauling considered essential.
Why does the route of administration matter so much? Absorption from the digestive tract saturates. Beyond a modest daily dose, blood levels plateau regardless of the number of tablets taken. Intravenous infusion bypasses that ceiling and can produce plasma concentrations tens of times higher.
How is vitamin C thought to affect cancer cells? At the concentrations achievable only by infusion, vitamin C can act as a pro-oxidant and generate hydrogen peroxide in the fluid surrounding tumors. Cancer cells, which often carry higher baseline oxidative stress and more reactive iron, appear more vulnerable to that damage than normal cells.
Does intravenous vitamin C cure cancer? No. No large, definitive randomized trial has shown that intravenous vitamin C prolongs life for most cancer patients. One pancreatic cancer trial reported roughly doubled median survival, but it was small and has not been replicated in a confirmatory study.
What benefit is most consistently reported? Quality of life. Patients receiving infusions alongside chemotherapy often report less fatigue, less pain, and fewer side effects such as nausea. That is a meaningful outcome, but distinct from survival.
Should people take more vitamin C supplements based on this research? No. The proposed mechanism depends entirely on concentrations that oral dosing cannot reach. Taking additional tablets does not move a person any closer to the effect, because absorption is already saturated.
Are infusions safe? They are generally well tolerated in trial settings, but problems can occur, particularly in people with impaired kidney function or certain rare inherited enzyme deficiencies. Appropriate use belongs in a clinical trial or supervised medical care, not a storefront wellness clinic.
